These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 29953622)

  • 21. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.
    Yadav AK; Renfrow JJ; Scholtens DM; Xie H; Duran GE; Bredel C; Vogel H; Chandler JP; Chakravarti A; Robe PA; Das S; Scheck AC; Kessler JA; Soares MB; Sikic BI; Harsh GR; Bredel M
    JAMA; 2009 Jul; 302(3):276-89. PubMed ID: 19602687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of c-erbB receptors and ligands in the bronchial epithelium of asthmatic subjects.
    Polosa R; Puddicombe SM; Krishna MT; Tuck AB; Howarth PH; Holgate ST; Davies DE
    J Allergy Clin Immunol; 2002 Jan; 109(1):75-81. PubMed ID: 11799369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
    Cornelissen B; Darbar S; Hernandez R; Kersemans V; Tullis I; Barber PR; Smart S; Vojnovic B; Reilly R; Vallis KA
    J Nucl Med; 2011 May; 52(5):776-83. PubMed ID: 21498540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth factor receptors and their ligands.
    Eppenberger U; Mueller H
    J Neurooncol; 1994; 22(3):249-54. PubMed ID: 7760103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer.
    Mitsui K; Yonezawa M; Tatsuguchi A; Shinji S; Gudis K; Tanaka S; Fujimori S; Sakamoto C
    BMC Cancer; 2014 Nov; 14():863. PubMed ID: 25416285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
    Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
    Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
    Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
    PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of different ligands on epidermal growth factor receptor (EGFR) nuclear translocation.
    Faria JAQA; de Andrade C; Goes AM; Rodrigues MA; Gomes DA
    Biochem Biophys Res Commun; 2016 Sep; 478(1):39-45. PubMed ID: 27462018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ErbB signaling regulates lineage determination of developing pancreatic islet cells in embryonic organ culture.
    Huotari MA; Miettinen PJ; Palgi J; Koivisto T; Ustinov J; Harari D; Yarden Y; Otonkoski T
    Endocrinology; 2002 Nov; 143(11):4437-46. PubMed ID: 12399441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
    Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
    Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines.
    Carrasco-García E; Saceda M; Grasso S; Rocamora-Reverte L; Conde M; Gómez-Martínez A; García-Morales P; Ferragut JA; Martínez-Lacaci I
    Exp Cell Res; 2011 Jun; 317(10):1476-89. PubMed ID: 21439954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma.
    Guo G; Gong K; Ali S; Ali N; Shallwani S; Hatanpaa KJ; Pan E; Mickey B; Burma S; Wang DH; Kesari S; Sarkaria JN; Zhao D; Habib AA
    Nat Neurosci; 2017 Aug; 20(8):1074-1084. PubMed ID: 28604685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DSE promotes aggressive glioma cell phenotypes by enhancing HB-EGF/ErbB signaling.
    Liao WC; Liao CK; Tsai YH; Tseng TJ; Chuang LC; Lan CT; Chang HM; Liu CH
    PLoS One; 2018; 13(6):e0198364. PubMed ID: 29864158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling.
    Moriai T; Kobrin MS; Hope C; Speck L; Korc M
    Proc Natl Acad Sci U S A; 1994 Oct; 91(21):10217-21. PubMed ID: 7937865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
    Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
    Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.
    Schulte A; Günther HS; Martens T; Zapf S; Riethdorf S; Wülfing C; Stoupiec M; Westphal M; Lamszus K
    Clin Cancer Res; 2012 Apr; 18(7):1901-13. PubMed ID: 22316604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
    Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
    BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.